























ful gimestat potassium（S‐１）と Cisplatin（CDDP）併
用療法の奏効率をあげるために Docetaxel（DTX）を加
えた３剤併用化学療法（DCS 療法）を開発し，Phase I／
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DCS 療法は，S‐１８０mg／m２を day１から day１４の２週
間経口投与し，day８に DTX ５０mg／m２および CDDP６０
mg／m２を点滴静注し，day１５より７日間休薬する計２１日
間を１コースとした１，２）（図１）。なお，悪心・嘔吐の予




S‐１投与開始直前（day１），DTX および CDDP 投与






















U／L，３．４±１．２ U／L，３．８±０．８ U／L であった。血清 DAO
活性平均値は，S‐１投与開始に伴い S‐１投与開始１週間







で１７．９±１５．６％，DTX および CDDP 投与１日（day８
から９）で２４．５±８．６％減少した。これに対し，消化管図１．DCS 療法の治療プロトコールと血清 DAO 活性の測定時期
図２．血清 DAO 活性の測定方法：Substrate solution：３０mM ca-
daverine in PIPES buffer（pH７．２）；Substrate solution：
０．６２５‐２０units/L DAO ; Color solution：１００μM DA‐６７，６
unit/ml peroxidase，５unit/ml ascorbate oxidase in MES
buffer（pH５．４）；Stop solution：３０mM diethyldithiocarbamate
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毒性が出現しなかった２例では，S‐１投与開始１週間後














































および CDDP 投与３日後）に，下痢は day１２（S‐１投与
開始１２日後，DTX および CDDP 投与４日後）に出現し












iting center : VC）が刺激されて生じる。その刺激経路と
して，①延髄に存在する化学受容体引き金帯（chemorecep-







症例 年齢 性 病期
消化管毒性（CTCAE Grade*） 消化管毒性
























































































今回の検討では，初回 DCS 療法施行時の血清 DAO 活
性の推移を評価することによって消化管毒性の出現を予
測できる可能性が考えられた。１コース終了時の血清
DAO 活性平均値は，開始直前の４．９U／L から３．８U／L へ
減少しており，２コース目以降にはより消化管毒性が出
現しやすくなる可能性も考えられる。今後，症例数を増
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SUMMARY
There are so many patients with advanced gastric cancer who undergo systemic chemother-
apy worldwide. The quality of life（QOL）of patients with gastric cancer who receive chemother-
apy is often lowed by various gastrointestinal toxicities during the chemotherapy. Nutrition is
also impaired by gastrointestinal toxicities. However, it is difficult to predict their occurrence in
advance and further there is no good serum marker for nutrition in the patients treated with che-
motherapy. Thus, it is important to objectively evaluate and predict the toxicity of the digestive
tract during cancer chemotherapy. Diamine Oxidase（DAO）is an enzyme that is expressed in in-
testinal epithelial cells. Recently it has been reported that DAO activity may reflect damage or at-
rophy of the intestinal villi, and therefore it may be a sensitive serum marker for nutritional state.
In this study, we measured serum DAO activity of patients with gastric cancer treated with sys-
temic chemotherapy, and investigated the correlation between DAO activity and gastrointestinal
toxicities. Six patients with gastric cancer, who were treated by docetaxel+cisplatin+S‐１combi-
nation chemotherapy, were enrolled. DAO activity was measured by sensitive colorimetric assay.
DAO activities diminished after treatment in４patients with moderate to severe gastrointestinal
toxicities. In contrast, they did not change in２patients with no gastrointestinal toxicities. Our
results may suggest that DAO activity is a good serum marker for the gastrointestinal toxicities as
well as nutrition state in patients who receive systemic chemotherapy. More large scale study is
needed to warrant.
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